KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Shares Outstanding (2017 - 2025)

Twist Bioscience (TWST) has disclosed Shares Outstanding for 7 consecutive years, with $57.4 million as the latest value for Q2 2023.

  • On a quarterly basis, Shares Outstanding rose 1.82% to $57.4 million in Q2 2023 year-over-year; TTM through Jun 2023 was $57.4 million, a 1.82% increase, with the full-year FY2022 number at $56.5 million, up 14.19% from a year prior.
  • Shares Outstanding was $57.4 million for Q2 2023 at Twist Bioscience, roughly flat from $57.1 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $57.4 million in Q2 2023 to a low of $28.0 million in Q1 2019.
  • A 5-year average of $46.3 million and a median of $48.9 million in 2021 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: skyrocketed 907.33% in 2019, then grew 1.55% in 2023.
  • Twist Bioscience's Shares Outstanding stood at $33.3 million in 2019, then skyrocketed by 46.17% to $48.6 million in 2020, then rose by 4.36% to $50.7 million in 2021, then rose by 11.41% to $56.5 million in 2022, then rose by 1.49% to $57.4 million in 2023.
  • Per Business Quant, the three most recent readings for TWST's Shares Outstanding are $57.4 million (Q2 2023), $57.1 million (Q1 2023), and $56.5 million (Q3 2022).